With reference to the earlier letter dated November 17, 2015 regarding the fire accident in one of the manufacturing blocks of the Company’s Cuddalore API facility, Shasun Pharmaceuticals has now informed that the Company have temporarily suspended the production, as directed by the Government authorities. The Company is working with the Government authorities to resume operations at the earliest. The Company confirms that there will be no material impact on the revenue of the group during the current financial year.
The above information is a part of company’s filings submitted to BSE.